首页> 美国卫生研究院文献>The British Journal of Ophthalmology >Possibilities and limitations of radioimmunoscintigraphy and conventional diagnostic modalities in choroidal melanoma.
【2h】

Possibilities and limitations of radioimmunoscintigraphy and conventional diagnostic modalities in choroidal melanoma.

机译:脉络膜黑色素瘤放射免疫闪烁成像和常规诊断方式的可能性和局限性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A prospective clinical study to assess the value of immunoscintigraphy with a monoclonal antibody (MoAb) against high molecular weight melanoma associated antigen (225.28S) was performed in 43 patients with choroidal melanoma; in six patients with a lesion suspected of being choroidal melanoma, and in seven patients with a benign lesion simulating a choroidal melanoma. The results of immunoscintigraphy in choroidal melanoma were compared with results of conventional diagnostic modalities like ultrasonography and fluorescein angiography. Planar scintigraphy showed a detection rate of 49% which is comparable with other studies. The detection with scintigraphy was correlated to the size of the choroidal melanoma. The use of single photon computed tomography did not increase the sensitivity of immunoscintigraphy. Ultrasonography yielded a correct diagnosis in 37 of 42 melanomas (88%). With fluorescein angiography a correct diagnosis was obtained in 11 of 30 melanomas (36.6%). The value of immunoscintigraphy with MoAb 225.28S in small choroidal melanomas is limited; its reliability increases in large tumours. Immunohistochemistry with MoAb 225.28S showed antigen expression in 95% of the stained tissue specimens of choroidal melanoma.
机译:对43例脉络膜黑色素瘤患者进行了一项前瞻性临床研究,以评估针对高分子量黑色素瘤相关抗原(225.28S)的单克隆抗体(MoAb)进行免疫闪烁扫描的价值;在六名怀疑是脉络膜黑色素瘤的病变患者中,七名在模拟了脉络膜黑色素瘤的良性病变中。脉络膜黑色素瘤的免疫闪烁扫描结果与超声和荧光素血管造影等常规诊断方式的结果进行了比较。平面闪烁显像法显示检出率为49%,与其他研究相当。闪烁显像的检测与脉络膜黑色素瘤的大小有关。单光子计算机断层扫描的使用不会增加免疫闪烁照相的敏感性。超声检查对42例黑色素瘤中的37例(88%)做出了正确的诊断。通过荧光素血管造影,在30个黑色素瘤中有11个(36.6%)获得了正确的诊断。 MoAb 225.28S免疫闪烁扫描在小型脉络膜黑色素瘤中的价值有限;在大肿瘤中其可靠性提高。用MoAb 225.28S进行的免疫组织化学显示,在95%的脉络膜黑色素瘤染色组织样本中抗原表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号